No Baby Blisters, a charity supporting babies living with epidermolysis bullosa (EB), announced its Hero Guardian Angel program and Fast Cure Plan, initiatives that provide immediate relief and contribute to ongoing research aimed at developing a lasting treatment.
More details can be found at https://nobabyblisters.org/
Epidermolysis bullosa is a rare genetic condition that causes the skin to blister and tear from minimal friction, often leading to chronic wounds, infection risk, and severe pain. For many families, routine tasks such as dressing, feeding, or helping a child walk can require constant care and specialized supplies.
Footwear, for example, is a medical consideration and not just a simple purchase. Research referenced in National Institutes of Health literature indicates that babies with EB benefit from soft, lightweight shoes with seamless interiors, flexible soles, and adjustable closures to reduce friction and accommodate bandaged feet. Without these precautions, even brief contact or pressure can result in new blistering.
No Baby Blisters says its Hero Guardian Angel program helps families meet these kinds of day-to-day needs, alongside covering essential items such as wound-care bandages, pain medications, and surgical support where required. As it notes, donations are directed to families managing EB, helping them maintain consistent access to supplies that reduce discomfort and prevent complications.
“Small details, like the wrong fabric or pressure point, can have serious consequences for a child with EB,” a representative said. “Supporting families means helping them manage those risks every day.”
The organization adds that contributions of varying sizes can make a measurable difference, noting that a $30 donation can help provide nearly two weeks of pain medication for a child, while ongoing monthly support allows families to plan around consistent care needs.
Alongside immediate support efforts, No Baby Blisters continues to advance its Fast Cure Plan, a program focused on developing a full-body systemic treatment for EB. The charity states that current approaches largely address symptoms, not the underlying condition, and that a broader therapeutic solution is needed.
Founder Aaron Tabor, MD, an NIH-funded skin researcher and founder of GENIE Therapeutics, leads the effort. His work in genetic skin therapies and related research fields informs the program’s long-term strategy.
The organization serves as an advocate for children living with EB and related conditions, working to provide access to care resources for families who may otherwise face significant barriers.
Visit https://nobabyblisters.org/ to learn more.